Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, Carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy. It is now available for online review at (http://informahealthcare.com/doi/abs/10.1517/14712590903321447).
Dr. Chan is the director of the Hematology/Oncology and Blood and Marrow Stem Cell Transplant Programs at the Texas Transplant Institute on the campus of Methodist Children's Hospital in San Antonio, Texas. He is also a principal investigator of the ExCell study currently evaluating StemEx. Dr. Petropoulos is a pediatric hematologist-oncologist at the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston, Texas, where the Phase I study of StemEx was conducted.
In the article Dr. Chan and Dr. Petropoulos note, "Early results suggested that carlecortemcel-l infusion ... may be associated with favorable non-relapse mortality rates…. Ex vivo expansion of umbilical cord blood (UCB) cells appears to be a logical approach to increase the availability of this source for hematopoietic stem cell (HSC) transplantation. Laboratory research showed that the critical element of success is to improve HSC proliferation without promoting differentiation. The manufacturing of carlecortemcel-l represents a novel methodology that fulfills this criterion. It is the only product that has reached the confirmatory stage of clinical development. A single institution study (Phase I study at M. D. Anderson Cancer Center) suggested that the infusion of these expanded cells … may improve transplant outcome in large-sized patients."
Innovative therapy targets and destroys leukemia stem cells